Health professional risk communication

New Safety Information Regarding Intelence (etravirine) and Severe Skin and Hypersensitivity Reactions - For Health Professionals

Starting date:
October 15, 2009
Posting date:
October 19, 2009
Type of communication:
Dear Healthcare Professional Letter
Subcategory:
Drugs
Source of recall:
Health Canada
Audience:
Healthcare Professionals
Identification number:
RA-170002063

This is duplicated text of a letter from Tibotec, a division of Janssen-Ortho Inc.
Contact the company for a copy of any references, attachments or enclosures.

Notice about Health Canada advisories

Health Canada Endorsed Important Safety Information on Intelence (etravirine)

October 15, 2009

Subject: New safety information regarding IntelenceFootnote 1 (etravirine) and severe skin and hypersensitivity reactions

Dear Health Care Professional,

Tibotec, a division of Janssen-Ortho Inc. ("Tibotec"), in collaboration with Health Canada, would like to inform you of important safety information regarding severe skin reactions in patients receiving combination therapy including INTELENCE (etravirine) tablets. Specifically, there have been post-marketing reports of severe hypersensitivity reactions sometimes accompanied by hepatic failure, and a report of a fatality due to toxic epidermal necrolysis.

  • Severe, potentially life-threatening, and fatal skin reactions have been reported. These include cases of Stevens-Johnson syndrome, toxic epidermal necrolysis and erythema multiforme. Hypersensitivity reactions have also been reported and were characterized by rash, constitutional findings, and sometimes organ dysfunction, including hepatic failure.
  • Discontinue INTELENCE immediately if signs or symptoms of severe skin reactions or hypersensitivity reactions develop (including, but not limited to, severe rash or rash accompanied by fever, general malaise, fatigue, muscle or joint aches, blisters, oral lesions, conjunctivitis, facial edema, hepatitis, eosinophilia). Clinical status including liver transaminases should be monitored and appropriate therapy initiated. Delay in stopping INTELENCE treatment after the onset of severe rash may result in a life-threatening reaction.

The cases within clinical and post-marketing experience illustrate the importance of clinical vigilance and familiarity with the signs and symptoms of severe skin rash and hypersensitivity reactions. Additionally, they underscore the importance of immediate discontinuation of INTELENCE in cases where severe rash or hypersensitivity reaction is suspected.

In Phase 3 clinical trials, Grade 3 and 4 rashes were reported in 1.3% of subjects receiving INTELENCE compared to 0.2% of placebo subjects. A total of 2% of HIV-1-infected patients receiving INTELENCE discontinued from Phase 3 trials due to rash. Rash occurred most commonly during the first 6 weeks of therapy.

The most frequently reported adverse drug reaction (ADR) of at least Grade 2 in severity in the Phase 3 studies was rash (9.0%). Stevens-Johnson syndrome, severe hypersensitivity reaction, and erythema multiforme were reported in < 0.1% of subjects during clinical development with INTELENCE. In general, rash was mild to moderate, occurred primarily in the second week of therapy and was infrequent after Week 4. Rash generally resolved within 1-2 weeks on continued therapy.

Tibotec is currently working with Health Canada to incorporate this new safety information in the Canadian Product Monograph for INTELENCE.

Managing marketed health product-related adverse reactions depends on health care professionals and consumers reporting them. Reporting rates determined on the basis of spontaneously reported post-marketing adverse reactions are generally presumed to underestimate the risks associated with health product treatments. Any case of serious skin reactions or hypersensitivity reactions, or other serious or unexpected adverse reactions in patients receiving INTELENCE should be reported to Tibotec or Health Canada at the following addresses:

Tibotec, a division of Janssen-Ortho Inc.
Drug Safety Department
19 Green Belt Drive
Toronto, Ontario, M3C 1L9
Tel: 1-800-567-3331 or Fax: 1-866-767-5865
dsscan@its.jnj.com

Any suspected adverse reaction can also be reported to:
Canada Vigilance Program
Marketed Health Products Directorate
HEALTH CANADA
Address Locator: 0701D
Ottawa, Ontario, K1A 0K9
Telephone: 613-957-0337 or Fax: 613-957-0335
To report an Adverse Reaction, consumers and health professionals may call toll free:
Telephone: 1-866-234-2345
Fax: 1-866-678-6789
CanadaVigilance@hc-sc.gc.ca

The Adverse Reaction Reporting Form and the Adverse Reaction Guidelines can be found on the Health Canada web site or in The Canadian Compendium of Pharmaceuticals and Specialties.

For other inquiries related to this communication, please contact Health Canada at:
Bureau of Gastroenterology, Infection and Viral Diseases (BGIVD)
E-mail: BGIVD_Enquiries@hc-sc.gc.ca
Telephone: 613-941-2566
Fax: 613-941-1183

Sincerely

original signed by

Cathy Lau, PhD.

Vice President
Regulatory Affairs
JANSSEN-ORTHO Inc.

References:

Footnote 1

All trademark rights used under license

Return to footnote 1 referrer